IIM
SYRE icon

INTECH Investment Management’s Spyre Therapeutics SYRE Stock Holding History

INTECH Investment Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.57M Buy
17,628
+1,185
+7% +$86.5K 0.01% 804
2026
Q1 		$829K Sell
16,443
-1,831
-10% -$69K 0.01% 1088
2025
Q4 		$599K Sell
18,274
-2,086
-10% -$54.5K 0.01% 1410
2025
Q3 		$341K Sell
20,360
-4,585
-18% -$74.8K ﹤0.01% 1768
2025
Q2 		$373K Buy
24,945
+4,517
+22% +$66.8K ﹤0.01% 1764
2025
Q1 		$330K Buy
20,428
+6,385
+45% +$133K ﹤0.01% 1828
2024
Q4 		$327K Buy
14,043
+5,672
+68% +$166K ﹤0.01% 1792
2024
Q3 		$246K Buy
+8,371
New +$233K ﹤0.01% 1622

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

INTECH Investment Management's SYRE Position: Q2 2026 in Review

INTECH Investment Management increased its Spyre Therapeutics (SYRE) stake by 7.2% in Q2 2026, buying an estimated $86.5K and bringing the position to 17,628 shares worth $1.57M. The position accounts for 0.01% of the portfolio, ranked #804.

INTECH Investment Management first reported a position in SYRE in Q3 2024 and has held it in 8 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • INTECH Investment Management held 17,628 shares of Spyre Therapeutics worth $1.57M as of Q2 2026.
  • INTECH Investment Management bought 1,185 Spyre Therapeutics shares in Q2 2026, an estimated $86.5K.
  • Spyre Therapeutics made up 0.01% of INTECH Investment Management's portfolio in Q2 2026, its #804 holding.
  • INTECH Investment Management first reported a position in Spyre Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on INTECH Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.